Skip to main content
MedPathMedPath Home
Clinical Trials/NCT04520672
NCT04520672
Recruiting
Not Applicable

Circulating Tumor Cells (CTC) in Cancer

University Hospital, Basel, Switzerland2 sites in 1 country3,000 target enrollmentOctober 1, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cancer
Sponsor
University Hospital, Basel, Switzerland
Enrollment
3000
Locations
2
Primary Endpoint
Overall survival (OS) in heterogeneous cancer population
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

This observational study with circulating tumor cells (CTC) count, isolation and analysis at several time points during disease progression is to investigate the role and biology of CTCs and clusters of CTCs in different cancer types. It also evaluates the role of CTCs as biomarkers, and aims at the identification of key signaling networks that are active in CTCs.

Registry
clinicaltrials.gov
Start Date
October 1, 2020
End Date
August 2030
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
University Hospital, Basel, Switzerland
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Adult cancer patients
  • •All patients with histology-based proved diagnosis of cancer, all stages and subtypes can be included. Precancerous lesions cannot be included.
  • •All patients with the diagnosis of a solid tumor including adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma, sarcoma
  • •Written pathology report must be available.
  • •Written informed consent.

Exclusion Criteria

  • •No written informed consent.
  • •No proved diagnosis of malignancy by pathology report.
  • •Patients with the diagnosis of blood cancer

Outcomes

Primary Outcomes

Overall survival (OS) in heterogeneous cancer population

Time Frame: Screening (Visit 1) until the date of death (assessed up to 240 months)

overall survival (OS) in heterogeneous cancer population

Change in total number of isolated CTCs

Time Frame: Through study completion, an average of 20 years

Change in total number of isolated CTCs

Secondary Outcomes

  • Progression free survival (PFS)(Through study completion, an average of 20 years)

Study Sites (2)

Loading locations...

Similar Trials

Completed
Not Applicable
Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation TherapyCirculating Tumor Cells
NCT02449837UNC Lineberger Comprehensive Cancer Center162
Completed
Not Applicable
Study of Circulating Tumor Cells Before and After Treatment in Patients With Metastatic MelanomaMelanoma
NCT01573494Centre Hospitalier Universitaire de Nice30
Completed
Not Applicable
Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast CancerLocally Advanced Breast CancerMetastatic (Stage IV) Breast CancerStage III-IV Breast Cancer or Inflammatory
NCT01048918City of Hope Medical Center280
Recruiting
Not Applicable
Analysis of circulating tumor cells(CTCs) and clinical significance of CTCs; human atrial natriuretic peptide during perioperative period for completely resected non-small cell lung cancer: a multicentre, open-label, randomised controlled trialnon-small cell lung cancer
JPRN-UMIN000024302Osaka University Graduate School of Medicine500
Recruiting
Not Applicable
Determining Circulating Tumour Cells (CTC) and other rare cells in cancer patients and for early detection screening
ACTRN12614001143617Dr Karin Ried2,000